Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-00489791 in Stage 1 and 2 Essential Hypertension
NCT00422461Phase 2Completed
- Sponsor
- Pfizer
- Start
- Feb 2007
- Primary completion
- Jan 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of PF-00489791 in essential hypertension (4 arms), sponsored by Pfizer. Primary endpoint: Change From Baseline in Mean Daytime Systolic Blood Pressure (SBP) as Measured by Ambulatory Blood Pressure Monitoring (ABPM) at Day 28. Started Feb 2007; status: completed.
02
Drugs
PF-00489791
03
Conditions
essential hypertension
Beyond the preview
Go deeper on NCT00422461.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00422461.